The Bureau of Industry and Security (BIS) published a final rule, in conjunction with a companion NRC rulemaking, transferring export licensing authority for non-nuclear deuterium from the Nuclear Regulatory Commission to the Commerce Department under the Export Administration Regulations. Deuterium and deuterium compounds (including heavy water) with a deuterium-to-hydrogen atom ratio exceeding 1:5000 that are intended for non-nuclear end use are added to ECCN 1C298 and made subject to Nuclear Proliferation (NP) controls on the Commerce Country Chart. Exports to NP column 2–controlled destinations require a BIS licence; deuterium for actual nuclear-reactor end use remains under NRC jurisdiction.

Analyst notesShow

Mechanism

Prior to this rule, all deuterium exports (regardless of end use) were regulated by the NRC under 10 CFR Part 110. As global commercial demand for deuterium in non-nuclear applications (e.g., heavy-water chemical synthesis, NMR solvents, isotope-labelled pharmaceuticals, semiconductor process gases) grew to dwarf nuclear-reactor end use, the NRC and BIS jointly restructured jurisdiction. The BIS final rule (FR Doc 2021-21509) adds Export Control Classification Number 1C298 to the Commerce Control List (CCL), covering:

> "Deuterium and any deuterium compound, including heavy water, in which the ratio of > deuterium atoms to hydrogen atoms exceeds 1:5000."

Exports and reexports of items meeting this definition for non-nuclear end use require a BIS licence to destinations with an "X" in the Nuclear Proliferation (NP) columns of the Commerce Country Chart (15 CFR Part 738, Supplement No. 1). The companion NRC rule (FR Doc 2021-21548) simultaneously removes the NRC's licensing authority for these non-nuclear-end-use shipments.

The split-jurisdiction framework clarifies the regulatory pathway:

Nuclear end use (reactor moderation, nuclear-weapon-adjacent) → NRC, 10 CFR Part 110.
Non-nuclear end use (commercial chemistry, pharma, semiconductors) → BIS, EAR ECCN 1C298.

Downstream implications

ECCN 1C298 becomes the upstream control node referenced by the August 2023 BIS rules that

added China and Macau to NP2 (see 2023-08-14-us-bis-china-macau-np2-controls), which materially tightened the practical licensing requirement for deuterium exports to China.

Exporters shipping NMR-grade deuterium oxide or deuterated solvents to NP2-listed countries

must now route licence applications through BIS rather than NRC.

The rule increases compliance surface for specialty-chemicals and pharmaceutical companies

that source or re-export deuterated compounds; the licence requirement is broadly applicable across NP2 destinations, not limited to any single country.

Open questions

Whether BIS will update ECCN 1C298 to reflect additional deuterium purity thresholds as

isotope-separation technology matures.

Interaction with future Allied (NSG/Wassenaar) harmonisation on deuterium controls,

particularly given China's heavy-water imports from non-OECD producers.

Sources

Primary: Federal Register Vol. 86 No. 191 — BIS final rule 2021-21509

Secondary: FD Associates — October 2021 Export Control Regulation Update

Loading…

Mechanism

> "Deuterium and any deuterium compound, including heavy water, in which the ratio of > deuterium atoms to hydrogen atoms exceeds 1:5000."

The split-jurisdiction framework clarifies the regulatory pathway:

Nuclear end use (reactor moderation, nuclear-weapon-adjacent) → NRC, 10 CFR Part 110.

Non-nuclear end use (commercial chemistry, pharma, semiconductors) → BIS, EAR ECCN 1C298.

Downstream implications

ECCN 1C298 becomes the upstream control node referenced by the August 2023 BIS rules that

added China and Macau to NP2 (see 2023-08-14-us-bis-china-macau-np2-controls), which materially tightened the practical licensing requirement for deuterium exports to China.

Exporters shipping NMR-grade deuterium oxide or deuterated solvents to NP2-listed countries

must now route licence applications through BIS rather than NRC.

The rule increases compliance surface for specialty-chemicals and pharmaceutical companies

that source or re-export deuterated compounds; the licence requirement is broadly applicable across NP2 destinations, not limited to any single country.